Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Edaphochelin A is a catecholate siderophore originally isolated from the soil-dwelling bacterium *Edaphobacter aggregans*. It is currently the lead candidate in the pipeline of Chemia, a biotechnology company that utilizes an artificial intelligence platform to mine the soil metagenome for novel bioactive small molecules. Siderophores like Edaphochelin A are high-affinity iron-chelating compounds used by microorganisms to scavenge ferric iron (Fe3+). In pharmaceutical development, Edaphochelin A is being explored for its potential to treat multidrug-resistant bacterial infections, likely by serving as a delivery vehicle in a 'Trojan horse' approach to bypass bacterial cell wall permeability barriers by leveraging active iron-uptake pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on edaphochelin A.